A pipeline powered bypassion

pipeline

Pre-Clinical

Phase 1

Phase 2

Phase 3
CARDIAC MUSCLE
Omecamtiv Mecarbil (Heart Failure)

AMGEN COLLABORATION
Next-Generation Cardiac Sarcomere Activator

AMGEN COLLABORATION
Cardiac Sarcomere Directed Compound

UNPARTNERED
SKELETAL MUSCLE
Tirasemtiv (ALS)

SUSPENDED*
Reldesemtiv (SMA)

ASTELLAS COLLABORATION
Reldesemtiv (COPD)

ASTELLAS COLLABORATION
Reldesemtiv (ALS)

ASTELLAS COLLABORATION
Reldesemtiv (Frailty)

ASTELLAS COLLABORATION
Next-Generation FSTA

ASTELLAS COLLABORATION
Research
Next Generation Skeletal Muscle Activators

ASTELLAS COLLABORATION
Other Muscle Biology Directed Research

type

indication

phase

CARDIAC MUSCLE

Omecamtiv Mecarbil (Heart Failure) Next-Generation Cardiac Sarcomere Activator Cardiac Sarcomere Directed Compound

3 Pre-Clinical Pre-Clinical

SKELETAL MUSCLE

Tirasemtiv (ALS) Reldesemtiv (SMA) Reldesemtiv (COPD) Reldesemtiv (ALS) Reldesemtiv (Frailty) Next-Generation FSTA

3 2 2 2 1 Pre-Clinical

Research

Next Generation Skeletal Muscle Activators Other Muscle Biology Directed Research

Pre-Clinical Pre-Clinical

*Astellas Option Outside North America & Europe

Reldesemtiv

With Astellas, Cytokinetics is developing reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA).

PUBLICATIONS

We’re proud to be a leader in muscle biology research. Read more about our work to develop potential therapies for people with diseases that rob them of key muscle functions.